APA
Polyzos A., Malamos N., Boukovinas I., Adamou A., Ziras N., Kalbakis K., Kakolyris S., Syrigos K., Papakotoulas P., Kouroussis C., Karvounis N., Vamvakas L., Christophyllakis C., Athanasiadis A., Varthalitis I., Georgoulias V. & Mavroudis D. (20100222). FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). : Breast cancer research and treatment.
Chicago
Polyzos Aristides, Malamos Nikolaos, Boukovinas Ioannis, Adamou Adamos, Ziras Nikolaos, Kalbakis Kostas, Kakolyris Stylianos, Syrigos Kostas, Papakotoulas Pavlos, Kouroussis Charalambos, Karvounis Nikolaos, Vamvakas Lambros, Christophyllakis Charalambos, Athanasiadis Athanasios, Varthalitis Ioannis, Georgoulias Vassilis and Mavroudis Dimitris. 20100222. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). : Breast cancer research and treatment.
Harvard
Polyzos A., Malamos N., Boukovinas I., Adamou A., Ziras N., Kalbakis K., Kakolyris S., Syrigos K., Papakotoulas P., Kouroussis C., Karvounis N., Vamvakas L., Christophyllakis C., Athanasiadis A., Varthalitis I., Georgoulias V. and Mavroudis D. (20100222). FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). : Breast cancer research and treatment.
MLA
Polyzos Aristides, Malamos Nikolaos, Boukovinas Ioannis, Adamou Adamos, Ziras Nikolaos, Kalbakis Kostas, Kakolyris Stylianos, Syrigos Kostas, Papakotoulas Pavlos, Kouroussis Charalambos, Karvounis Nikolaos, Vamvakas Lambros, Christophyllakis Charalambos, Athanasiadis Athanasios, Varthalitis Ioannis, Georgoulias Vassilis and Mavroudis Dimitris. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). : Breast cancer research and treatment. 20100222.